Trial Profile

A phase II, randomized, double blind study to evaluate the efficacy and safety of AMY109 in women with endometriosis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMY 109 (Primary) ; Desogestrel (Primary)
Indications Endometriosis
Focus Therapeutic Use
Acronyms ACERS
Sponsors Chugai Pharmaceutical

Most Recent Events

25 Apr 2024 Recruitment completion is expected on 31/07/2025 according to ISRCTN Clinical Trials Registry Record.
25 Apr 2024 Planned number of patients changed from 80 to 120.
27 Jul 2023 Planned number of patients changed from 63 to 80.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com